Insights into Endometriosis Organoids Based on Uterine Tissue Engineering: A Mini-review

Zeinab Nurian, Zeinan Nurian, Alireza Ebrahimzadeh, Alireza Ebrahimzadeh‐Bideskan, Fatemeh Alipour, Hengameh Dortaj
Current stem cell research & therapy · 2025 · vol. 21(1) , pp. 1–10 · doi:10.2174/011574888x360426250529055140 · PMID:40491370 · W4411189154
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This review explores how uterine organoids and decellularized tissue scaffolds improve in vitro modeling of endometrial diseases, offering potential for drug screening and regenerative therapies.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis is a chronic condition where tissue similar to the endometrium grows outside the uterus, affecting 5-10% of women and causing pelvic pain, painful periods, and infertility. Diseases of the endometrium, the lining of the uterus, can lead to a variety of reproductive health issues, including infertility, irregular bleeding, and endometrial cancer. Researchers have developed advanced in vitro systems using uterine organoids and decellularized tissue scaffolds to understand and model these diseases. The main limitations of traditional 2D monolayer cultures include reduced biological activity, reduced hormone responsiveness, and lack of interaction with ECM. Researchers have investigated 3D culture approaches to address these shortcomings, such as scaffold-free organoids and decellularized tissue scaffolds. Organoid systems can better recapitulate the cellular heterogeneity and physiological functions of the native endometrium. Decellularization protocols have been optimized to generate intact uterine scaffolds that preserve the structural and compositional features of the ECM. Implantation of these bioscaffolds into animal models demonstrated their biocompatibility and regenerative potential. Further refinements of organoid and scaffold technologies, including chemically defined matrices and organ-on-a-chip platforms, will improve our ability to model the uterus. Integration of these advanced in vitro models with patient-derived cells will enable personalized disease modeling and the development of targeted therapies. The combination of organoids, decellularized scaffolds, and microfluidic technologies holds great potential for exploring reproductive biology, drug screening, and developing regenerative therapies for uterine diseases and infertility.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (37)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-19T00:31:16.128783+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK